Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
| Title: | Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. |
|---|---|
| Authors: | Bonderman, Diana; Ghio, Stefano; Felix, Stephan B; Ghofrani, Hossein-Ardeschir; Michelakis, Evangelos; Mitrovic, Veselin; Oudiz, Ronald J; Boateng, Francis; Scalise, Andrea-Viviana; Roessig, Lothar; Semigran, Marc J; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group |
| Source: | Circulation; 7/30/2013, Vol. 128 Issue 5, p502-511, 10p |
| Database: | Complementary Index |